CTOs on the Move

Kallyope

www.kallyope.com

 
At Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the gut informs our brains about our well-being, metabolism, and nutritional state. The gut-brain axis—the communication highway between our gut and our brain—offers an unprecedented opportunity to access and influence brain centers involved in fundamental human processes. An understanding of the biology mediated by the gut and gut-brain circuits will change the way we think about food, nutrition, and human physiology. Founded and headquartered in New York City, we are developing an industry-leading platform to harness the gut-brain axis. Our cross-disciplinary biotechnology team ...
  • Number of Employees: 100-250
  • Annual Revenue: $0-1 Million
  • www.kallyope.com
  • 430 East 29th Street 8th Floor
    New York, NY USA 10016
  • Phone: N/A

Executives

Name Title Contact Details

Funding

Kallyope raised $66M on 02/22/2018
Kallyope raised $21M on 12/05/2018
Kallyope raised $112M on 03/05/2020

Similar Companies

Isis Pharmaceuticals Inc

Isis Pharmaceuticals Inc is a Carlsbad, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Roche NimbleGen

Roche NimbleGen, Inc. is a Madison, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Molecular Pharmacology Limited (USA)

Molecular Pharmacology Limited (USA) is a West Hollywood, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Irvine Scientific

Irvine Scientific is a Santa Ana, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ambrx

Ambrx is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop next generation antibody drug conjugates (ADCs) and other engineered therapies to modulate the immune system. Ambrx is advancing a focused portfolio of clinical and preclinical programs designed to optimize efficacy and safety in multiple cancer indications. Specifically, ARX517, its proprietary antibody-drug conjugates (ADC) targeting the prostate-specific membrane antigen (PSMA) and ARX788, its proprietary ADC targeting HER2. Ambrx spun out of The Scripps Research Institute in 2003 and has several other product candidates involving ADCs and other aspects of Ambrx`s protein engineering technology.